Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic cyclophosphamide + celecoxib + dexamethasone in advanced hormone-refractory prostate cancer
2005-005967-27Phase 2Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Feb 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, celecoxib and dexamethasone in prostate cancer (PCa), sponsored by Azienda USL Toscana Nord Ovest. Primary endpoints: PSA response, Objective response by RECIST and 1 more. Started Feb 2006; status: active.
02
Drugs
cyclophosphamidecelecoxibdexamethasone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005967-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005967-27.